
Page#1
CONSOLIDATED STATEMENTS OF OPERATIONS
 For the year ended December 31,
(in millions, except per share data) 2018  2017  2016
Net sales $ 3,345.5  $ 2,786.0  $ 2,748.0
Operating costs and expenses: 
Cost of sales 2,156.2  1,770.9  1,758.3
Selling, general and administrative 721.0  605.9  610.6
Asbestos provision —  —  192.4
Restructuring charges 7.2  13.0  —
Acquisition-related and integration charges 19.8  7.8  —
 2,904.2  2,397.6  2,561.3
Operating profit 441.3  388.4  186.7
Other income (expense): 
Interest income 2.3  2.5  1.9
Interest expense (50.9)  (36.1)  (36.5)
Miscellaneous income, net 18.7  12.7  12.0
 (29.9)  (20.9)  (22.6)
Income before income taxes 411.4  367.5  164.1
Provision for income taxes 75.9  195.0  40.3
Net income before allocation to noncontrolling interests 335.5  172.5  123.8
Less: Noncontrolling interest in subsidiaries’ (loss) earnings (0.1)  0.7  1.0
Net income attributable to common shareholders $ 335.6  $ 171.8  $ 122.8
 
Basic earnings per share $ 5.63  $ 2.89  $ 2.10
Weighted average basic shares outstanding 59.6  59.4  58.5
 
Diluted earnings per share $ 5.50  $ 2.84  $ 2.07
Weighted average diluted shares outstanding 61.0  60.4  59.3
 
See
Notes
to
Consolidated
Financial
Statements
Page 40
Page#2
CONSOLIDATED BALANCE SHEETS
 
  Balance as of December 31,
(in millions, except shares and per share data)  2018  2017
Assets 
Current assets: 
Cash and cash equivalents  $ 343.4  $ 706.2
Current insurance receivable — asbestos  16.0  25.0
Accounts receivable, net  515.8  418.4
Inventories  411.5  349.3
Other current assets  76.2  19.6
Total current assets  1,362.9  1,518.5
Property, plant and equipment, net  599.1  282.4
Insurance receivable — asbestos  75.0  90.1
Long-term deferred tax assets  18.8  104.2
Other assets  101.4  114.6
Intangible assets, net  481.8  276.8
Goodwill  1,403.7  1,206.9
Total assets  4,042.7  $ 3,593.5
Liabilities and equity 
Current liabilities: 
Current maturities of long-term debt  $ 6.9  $ 249.4
Accounts payable  329.2  247.4
Current asbestos liability  66.0  85.0
Accrued liabilities  337.1  252.1
U.S. and foreign taxes on income  1.0  3.6
Total current liabilities  740.2  837.5
Long-term debt  942.3  494.1
Accrued pension and postretirement benefits  244.0  240.5
Long-term deferred tax liability  53.2  44.9
Long-term asbestos liability  451.3  520.3
Other liabilities  84.6  107.7
Commitments and contingencies (Note 11)  
Equity: 
Preferred shares, par value $.01; 5,000,000 shares authorized  —  —
Common shares, par value $1.00; 200,000,000 shares authorized; 72,426,139 shares issued; 59,508,401 shares outstanding
(59,411,636 in 2017)  72.4  72.4
Capital surplus  303.5  291.7
Retained earnings  2,072.1  1,813.3
Accumulated other comprehensive loss  (447.6)  (380.1)
Treasury stock; 12,917,713 treasury shares (13,014,503 in 2017)  (476.2)  (452.1)
Total shareholders’ equity  1,524.2  1,345.2
Noncontrolling interest  2.9  3.3
Total equity  1,527.1  1,348.5
Total liabilities and equity  $ 4,042.7  $ 3,593.5
See
Notes
to
Consolidated
Financial
Statements

Page 42
Page#3
CONSOLIDATED STATEMENTS OF CASH FLOWS
 For year ended December 31,
(in millions) 2018  2017  2016
Operating activities: 
Net income attributable to common shareholders $ 335.6  $ 171.8  $ 122.8
Noncontrolling interest in subsidiaries' (loss) earnings (0.1)  0.7  1.0
Net income before allocations to noncontrolling interests 335.5  172.5  123.8
Asbestos provision —  —  192.4
Loss (gain) on deconsolidation of joint venture 1.7  (1.0)  —
Gain on sale of property related to facility consolidation —  (11.1)  —
Depreciation and amortization 120.0  72.7  67.4
Stock-based compensation expense 21.6  21.8  21.7
Defined benefit plans and postretirement credit (15.0)  (8.5)  (9.1)
Deferred income taxes 47.7  102.3  (25.1)
Cash provided by operating working capital 16.3  54.0  27.0
Defined benefit plans and postretirement contributions (59.8)  (13.2)  (8.8)
Environmental payments, net of reimbursements (6.3)  (6.3)  (11.6)
Payments for asbestos-related fees and costs, net of insurance recoveries (63.9)  (62.5)  (56.0)
Other 16.0  (3.2)  (3.6)
Total provided by operating activities 413.8  317.5  318.1
 
Investing activities: 
Capital expenditures (108.8)  (49.0)  (51.5)
Proceeds from disposition of capital assets 1.9  22.3  0.9
Impact of deconsolidation of joint ventures 2.6  (5.2)  —
Payments for acquisitions, net of cash acquired (648.0)  (54.8)  —
 Total used for investing activities (752.3)  (86.7)  (50.6)
 
Financing activities: 
Dividends paid (83.5)  (78.4)  (77.2)
Reacquisition of shares on open market (50.1)  (25.0)  —
Stock options exercised, net of shares reacquired 16.1  25.2  26.4
Debt issuance costs (5.4)  (2.6)  —
Repayment of long-term debt (452.2)  —  —
Repayment of short-term debt (100.0)  —  —
Repayment of commercial paper —  —  (49.6)
Proceeds from issuance of long-term debt 567.2  —  —
Proceeds from issuance of short-term debt 100.0  —  —
 Total used for financing activities (7.9)  (80.8)  (100.4)
Effect of exchange rates on cash and cash equivalents (16.4)  46.5  (20.9)
(Decrease) increase in cash and cash equivalents (362.8)  196.5  146.2
Cash and cash equivalents at beginning of period 706.2  509.7  363.5
Cash and cash equivalents at end of period $ 343.4  $ 706.2  $ 509.7
 
Detail of cash provided by (used for) operating working capital: 
Accounts receivable $ 4.8  $ (10.1)  $ (6.2)
Inventories (38.8)  6.4  24.9
Other current assets (11.4)  0.8  (2.4)
Accounts payable 37.0  17.5  5.5
Accrued liabilities 40.9  30.8  9.6
U.S. and foreign taxes on income (16.2)  8.6  (4.4)
Total $ 16.3  $ 54.0  $ 27.0
Supplemental disclosure of cash flow information: 